Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization: an Open-labeled Multicenter Randomized Controlled Study

When children receive a new kidney, it's really important for doctors to regularly check that the new kidney is working well and that the body isn't trying to reject it. They also need to make sure the medicines given to stop rejection, like tacrolimus, are at the right level to prevent problems. Currently, a common way to do this is by taking small samples from the kidney, called biopsies. While these are very helpful, they do involve a small procedure.

This study, called MONITOR, is exploring new ways to check on the kidney's health and medicine levels that are less invasive. It's looking at using special blood tests: one called 'donor-derived cell-free DNA' (dd-cfDNA) and another for 'virus-specific T cells' (T-Vis). The idea is that these blood tests might be able to tell doctors if the kidney is doing well or if there are any issues, potentially reducing how often children need to have a biopsy.

The researchers also hope that using these blood tests will help doctors fine-tune the amount of anti-rejection medicine each child receives. This is important because too much medicine can have side effects, and too little might not protect the new kidney enough. If successful, this research could lead to a kinder and more personalised way of caring for children after a kidney transplant, making monitoring easier for them and their families.